Avalanche Biotechnologies, Inc.

Redwood City, CA 94061

Market Performance

NASDAQ: AAVL
52 Week High $4.20
52 Week Low $2.40

SBIR Award Summary

Total Number of Awards 3
Total Value of Awards $510K
First Award Date 09/30/12
Most Recent Award Date 09/30/12

Key Personnel

Last Name Name Awards Contact
Demetriades Anna Maria Demetriades 2
Chalberg Thomas W Chalberg 1

3 Awards Won

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-11-097
Budget: 09/30/12 - 08/31/13

DESCRIPTION (provided by applicant): The objective of this proposal is to examine the efficacy of a novel adeno-associated virus (AAV) variant, ShH10, expressing neurotrophic factors for the treatment of glaucoma. Glaucoma is the second leading cause of blindness with high associated societal costs, and is expected to grow. The hallmark of glauc...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 09/30/12 - 08/31/13

DESCRIPTION (provided by applicant): The objective of this proposal is to examine the efficacy of novel adeno-associated virus (AAV) variants expressing soluble FLT-1, a potent inhibitor of VEGF-mediated neovascularization and vascular permeability, to treat diabetic macular edema (DME). DME is an advanced form of diabetic retinopathy and the le...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-11-097
Budget: 09/30/12 - 08/31/13

DESCRIPTION (provided by applicant): The objective of this proposal is to examine the efficacy of a novel adeno-associated virus (AAV) variant, ShH10, expressing neurotrophic factors for the treatment of glaucoma. Glaucoma is the second leading cause of blindness with high associated societal costs, and is expected to grow. The hallmark of glauc...